A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer

<b>Background/Objectives</b>: Regulatory T cells (Treg) suppress immunity in the tumor microenvironment, are linked to poor prognosis across breast cancer subtypes, and suppress the cytolytic function of cytotoxic CD8+ T cells. Denileukin diftitox, a diphtheria toxin (DT)/IL-2 fusion pro...

Full description

Bibliographic Details

Published in:	Vaccines
Main Authors:	William R. Gwin, Lupe G. Salazar, James Y. Dai, Doreen Higgins, Andrew L. Coveler, Jennifer S. Childs, Rosie Blancas, Yushe Dang, Jessica Reichow, Meredith Slota, Hailing Lu, Mary L. Disis
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Subjects:	denileukin diftitox regulatory T-cells breast cancer immunity tumor microenvironment
Online Access:	https://www.mdpi.com/2076-393X/13/2/117